These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 11295571)
1. Angiotensin III: a central regulator of vasopressin release and blood pressure. Reaux A; Fournie-Zaluski MC; Llorens-Cortes C Trends Endocrinol Metab; 2001; 12(4):157-62. PubMed ID: 11295571 [TBL] [Abstract][Full Text] [Related]
2. [Identification of metabolic pathways of brain angiotensin II and angiotensin III: predominant role of angiotensin III in the control of vasopressin secretion]. Llorens-Cortes C C R Seances Soc Biol Fil; 1998; 192(4):607-18. PubMed ID: 9842467 [TBL] [Abstract][Full Text] [Related]
3. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure. Reaux A; Iturrioz X; Vazeux G; Fournie-Zaluski MC; David C; Roques BP; Corvol P; Llorens-Cortes C Biochem Soc Trans; 2000; 28(4):435-40. PubMed ID: 10961935 [TBL] [Abstract][Full Text] [Related]
4. Aminopeptidase A inhibitors as centrally acting antihypertensive agents. Bodineau L; Frugière A; Marc Y; Claperon C; Llorens-Cortes C Heart Fail Rev; 2008 Sep; 13(3):311-9. PubMed ID: 18175217 [TBL] [Abstract][Full Text] [Related]
5. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Réaux A; de Mota N; Zini S; Cadel S; Fournié-Zaluski MC; Roques BP; Corvol P; Llorens-Cortès C Neuroendocrinology; 1999 May; 69(5):370-6. PubMed ID: 10343178 [TBL] [Abstract][Full Text] [Related]
6. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Zini S; Fournie-Zaluski MC; Chauvel E; Roques BP; Corvol P; Llorens-Cortes C Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11968-73. PubMed ID: 8876246 [TBL] [Abstract][Full Text] [Related]
7. Role of angiotensin III in hypertension. Reaux-Le Goazigo A; Iturrioz X; Fassot C; Claperon C; Roques BP; Llorens-Cortes C Curr Hypertens Rep; 2005 Apr; 7(2):128-34. PubMed ID: 15748538 [TBL] [Abstract][Full Text] [Related]
8. Aminopeptidase A inhibitors as potential central antihypertensive agents. Reaux A; Fournie-Zaluski MC; David C; Zini S; Roques BP; Corvol P; Llorens-Cortes C Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13415-20. PubMed ID: 10557335 [TBL] [Abstract][Full Text] [Related]
9. Influence of dietary sodium on the blood pressure and renal sympathetic nerve activity responses to intracerebroventricular angiotensin II and angiotensin III in anaesthetized rats. Houghton BL; Huang C; Johns EJ Exp Physiol; 2010 Feb; 95(2):282-95. PubMed ID: 19880539 [TBL] [Abstract][Full Text] [Related]
10. A new strategy for treating hypertension by blocking the activity of the brain renin-angiotensin system with aminopeptidase A inhibitors. Gao J; Marc Y; Iturrioz X; Leroux V; Balavoine F; Llorens-Cortes C Clin Sci (Lond); 2014 Aug; 127(3):135-48. PubMed ID: 24697296 [TBL] [Abstract][Full Text] [Related]
11. Roles of brain angiotensins II and III in thirst and sodium appetite. Wilson WL; Roques BP; Llorens-Cortes C; Speth RC; Harding JW; Wright JW Brain Res; 2005 Oct; 1060(1-2):108-17. PubMed ID: 16182260 [TBL] [Abstract][Full Text] [Related]
12. The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Marc Y; Llorens-Cortes C Prog Neurobiol; 2011 Oct; 95(2):89-103. PubMed ID: 21763394 [TBL] [Abstract][Full Text] [Related]
13. Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems. Llorens-Cortes C; Kordon C J Neuroendocrinol; 2008 Mar; 20(3):279-89. PubMed ID: 18194430 [TBL] [Abstract][Full Text] [Related]
14. [A comparison between the effects of angiotensin II and angiotensin III injected into the third cerebral ventricle on vasopressin secretion in conscious rats (author's transl)]. Yamaguchi K; Negoro H; Hama H; Kamoi K; Sakaguchi T Nihon Naibunpi Gakkai Zasshi; 1979 Oct; 55(10):1286-95. PubMed ID: 510629 [TBL] [Abstract][Full Text] [Related]
15. [Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension]. Llorens-Cortès C Biol Aujourdhui; 2014; 208(3):217-24. PubMed ID: 25474003 [TBL] [Abstract][Full Text] [Related]
16. Systemic effects of angiotensin III in conscious dogs during acute double blockade of the renin-angiotensin-aldosterone-system. Gammelgaard I; Wamberg S; Bie P Acta Physiol (Oxf); 2006 Oct; 188(2):129-38. PubMed ID: 16948800 [TBL] [Abstract][Full Text] [Related]
17. Role of intracerebral angiotensin receptors in the regulation of vasopressin release and the cardiovascular system. Shoji M; Kimura T; Matsui K; Ota K; Iitake K; Inoue M; Yoshinaga K Neuroendocrinology; 1986; 43(2):239-44. PubMed ID: 3014365 [TBL] [Abstract][Full Text] [Related]
18. Important role for angiotensin III and IV in the brain renin-angiotensin system. Wright JW; Harding JW Brain Res Brain Res Rev; 1997 Sep; 25(1):96-124. PubMed ID: 9370053 [TBL] [Abstract][Full Text] [Related]
19. Angiotensin III: a physiological relevant peptide of the renin angiotensin system. Yugandhar VG; Clark MA Peptides; 2013 Aug; 46():26-32. PubMed ID: 23692861 [TBL] [Abstract][Full Text] [Related]
20. Angiotensin II-induced vasopressin release is attenuated by central atrial natriuretic factor. Casto R; Keiler I; Schroeder G; Stock G Clin Exp Hypertens A; 1987; 9(1):81-94. PubMed ID: 2953510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]